$NTRA

ROSENMAN HERM sold $4.1M of NTRA

ROSENMAN HERM sold 16,530 shares of Natera, Inc. (NTRA) at $250.00 ($4.13M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROSENMAN HERM
Published Jun 27, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 27, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale is a director open-market transaction executed under a pre-arranged 10b5-1 plan, which typically limits inference about management’s forward outlook.

02

Market read

This provides incremental insider-activity information but no new operational, financial, or regulatory catalyst.

03

What to watch

Traders may over-weight the sale size; without additional context (e.g., total insider holdings trend, other concurrent filings), the signal is weak.

Relevance 5/10Novelty 4/10Timing: latest Form 4 filed late June; sale dated 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera (NTRA) disclosed a director open-market sale of 16,530 shares at $250/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which generally dampens interpretability versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a view on near-term prospects.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction; director sold 16,530 shares at $250/share.

  • ROSENMAN HERM

    Director who reported the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.